The Potential Role of Soluble Fibre in the Treatment of Hypercholesterolaemia

Overview

Journal Postgrad Med J

Publisher Oxford University Press

Specialty General Medicine

Date 1998 Nov 4

PMID 9799908

Citations 2

Authors

A J Coats

Affiliations

Soon will be listed here.

Abstract

The three major modifiable coronary risk factors are smoking, hypertension, and hypercholesterolaemia. Serum cholesterol levels are above the desirable level of 5.2 mmol/l in 79% of men and 65% of women aged between 35 and 50 years and thus are an important target for intervention. In this paper, the role of nonpharmacological intervention with soluble fibre in treating mild to moderate primary hypercholesterolaemia is reviewed. Evidence from controlled studies shows that soluble fibre can be effective in lowering cholesterol by clinically significant amounts. It is stressed, however, that risk factors for coronary heart disease are interactive and attention is shifting to addressing multiple rather that individual factors.

Citing Articles

Effect of cigarette smoking on smoking biomarkers, blood pressure and blood lipid levels among Sri Lankan male smokers.

Herath P, Wimalasekera S, Amarasekara T, Fernando M, Turale S Postgrad Med J. 2023; 98(1165):848-854.

PMID: 37063035 PMC: 9613865. DOI: 10.1136/postgradmedj-2021-141016.

Current, new and future treatments in dyslipidaemia and atherosclerosis.

Chong P, Bachenheimer B Drugs. 2000; 60(1):55-93.

PMID: 10929930 DOI: 10.2165/00003495-200060010-00005.

References

Goldbourt U, Holtzman E, NEUFELD H . Total and high density lipoprotein cholesterol in the serum and risk of mortality: evidence of a threshold effect. Br Med J (Clin Res Ed). 1985; 290(6477):1239-43. PMC: 1415871. DOI: 10.1136/bmj.290.6477.1239. View

Pyorala K, De Backer G, Graham I, Poole-Wilson P, Wood D . Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis. 1994; 110(2):121-61. DOI: 10.1016/0021-9150(94)90200-3. View

Martin M, Hulley S, Browner W, Kuller L, Wentworth D . Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986; 2(8513):933-6. DOI: 10.1016/s0140-6736(86)90597-0. View

Anderson J, Zettwoch N, Feldman T, Oeltgen P, BISHOP C . Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men. Arch Intern Med. 1988; 148(2):292-6. View

Bell L, Hectorne K, Reynolds H, Balm T, Hunninghake D . Cholesterol-lowering effects of psyllium hydrophilic mucilloid. Adjunct therapy to a prudent diet for patients with mild to moderate hypercholesterolemia. JAMA. 1989; 261(23):3419-23. DOI: 10.1001/jama.261.23.3419. View

Levin E, Miller V, Muesing R, Stoy D, Balm T, Larosa J . Comparison of psyllium hydrophilic mucilloid and cellulose as adjuncts to a prudent diet in the treatment of mild to moderate hypercholesterolemia. Arch Intern Med. 1990; 150(9):1822-7. View

Bell L, Hectorn K, Reynolds H, Hunninghake D . Cholesterol-lowering effects of soluble-fiber cereals as part of a prudent diet for patients with mild to moderate hypercholesterolemia. Am J Clin Nutr. 1990; 52(6):1020-6. DOI: 10.1093/ajcn/52.6.1020. View

Anderson J, Floore T, Geil P, ONeal D, Balm T . Hypocholesterolemic effects of different bulk-forming hydrophilic fibers as adjuncts to dietary therapy in mild to moderate hypercholesterolemia. Arch Intern Med. 1991; 151(8):1597-602. View

Ramsay L, Yeo W, Jackson P . Dietary reduction of serum cholesterol concentration: time to think again. BMJ. 1991; 303(6808):953-7. PMC: 1671346. DOI: 10.1136/bmj.303.6808.953. View

10.

Haskell W, Spiller G, Jensen C, Ellis B, Gates J . Role of water-soluble dietary fiber in the management of elevated plasma cholesterol in healthy subjects. Am J Cardiol. 1992; 69(5):433-9. DOI: 10.1016/0002-9149(92)90980-d. View

11.

Watts G, Lewis B, Brunt J, Lewis E, Coltart D, Smith L . Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992; 339(8793):563-9. DOI: 10.1016/0140-6736(92)90863-x. View

12.

Betteridge D, Dodson P, Durrington P, Hughes E, Laker M, Nicholls D . Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J. 1993; 69(811):359-69. PMC: 2399810. DOI: 10.1136/pgmj.69.811.359. View

13.

Law M, Wald N, Thompson S . By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?. BMJ. 1994; 308(6925):367-72. PMC: 2539460. DOI: 10.1136/bmj.308.6925.367. View

14.

Glore S, van Treeck D, Knehans A, Guild M . Soluble fiber and serum lipids: a literature review. J Am Diet Assoc. 1994; 94(4):425-36. DOI: 10.1016/0002-8223(94)90099-x. View

15.

Betteridge D . Cholesterol lowering and CHD prevention: time to get on with it. Br J Clin Pract. 1994; 48(3):115-7. View

16.

Neil H, Roe L, Godlee R, Moore J, Clark G, Brown J . Randomised trial of lipid lowering dietary advice in general practice: the effects on serum lipids, lipoproteins, and antioxidants. BMJ. 1995; 310(6979):569-73. PMC: 2548942. DOI: 10.1136/bmj.310.6979.569. View

17.

Shepherd J, Cobbe S, Ford I, Isles C, LORIMER A, Macfarlane P . Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20):1301-7. DOI: 10.1056/NEJM199511163332001. View

18.

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

19.

Stamler J, Wentworth D, Neaton J . Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256(20):2823-8. View